HEALTHCARE ECONOMICS PUBLICATIONS & ABSTRACTS
Healthcare Economics Data
Evidence / Healthcare Economics
Economic Evaluation of the 70-gene Prognosis-Signature (MammaPrint®) in Hormone Receptor-Positive, Lymph Node-Negative, Human Epidermal Growth Factor Receptor Type 2-Negative Early Stage Breast Cancer in Japan
PUBLICATION: Breast Cancer Res Treat. 2012 Jun;133(2):759-68. doi: 10.1007/s10549-012-1979-7. AUTHORS: Kondo M., Hoshi S.L., Ishiguro H., Toi M. SUMMARY: The introduction of the assay into Japanese practice of ER+, LN−, HER2− ESBC treatment by including it to Japan’s social health insurance benefit package has a reasonable chance to be judged Read More
Cost Effectiveness of Gene Expression Profiling for Early Stage Breast Cancer: a Decision-Analytic Mode
PUBLICATION: Cancer. 2012 Oct 15;118(20):5163-70. doi: 10.1002/cncr.27443. Epub 2012 Feb 22. AUTHORS: Yang M., Rajan S., Issa A.M. SUMMARY: The model suggested that MammaPrint is a more cost‐effective GEP test compared with Oncotype DX at a threshold willingness‐to‐pay of $50,000 per QALY. Read more: Yang et al_2012_Cancer_Cost Effectiveness of Gene Read More
Head-to-Head Comparison of the 70-gene Signature Versus the 21-Gene Assay: Cost-Effectiveness and the Effect of Compliance
PUBLICATION: Breast Cancer Res Treat. 2012 Jan;131(2):627-36. doi: 10.1007/s10549-011-1769-7. Epub 2011 Sep 24. AUTHORS: Retèl V.P., Joore M.A., van Harten W.H. SUMMARY: The 21-gene has the highest probability of being cost-effective when focusing on cost/LY, while focusing on cost/QALY, the 70-gene signature was most cost-effective. Read more: Breast Cancer Res Read More
Cost-effectiveness of 70-gene MammaPrint Signature in Node-Negative Breast Cancer
PUBLICATION: Am J Manag Care. 2010 Dec 1;16(12):e333-42. AUTHORS: Chen E., Tong K.B., Malin J.L. SUMMARY: 70-gene signature reclassified 29% of patients and spared 10% of patients from chemotherapy. Results of this modeling analysis suggest that treatment guided by 70-gene signature may be associated with a decrease in chemotherapy use Read More
Cost-effectiveness of the 70-gene Signature Versus St. Gallen Guidelines and Adjuvant Online for Early Breast Cancer
PUBLICATION: Eur J Cancer. 2010 May;46(8):1382-91. doi: 10.1016/j.ejca.2010.02.035. Epub 2010 Mar 30. AUTHORS: Retèl V.P., Joore M.A., Knauer M., Linn S.C., Hauptmann M., Harten W.H. SUMMARY: Pooled analysis: he 70-gene has the highest probability of being cost-effective for a willingness to pay for a QALY higher than euro12.000. Sankt Gallen Read More